☆ 4.4 Review

Cholangiocarcinoma: Molecular Abnormalities and Cells of Origin

TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples

Eleonora Loi et al.

Summary: In this study, we aimed to identify BTC-specific DNA methylation alterations. By performing a genome-wide methylation study and validating the findings in multiple samples, we successfully identified and validated BTC-specific DNA methylation alterations in over 200 BTC samples. Additionally, we discovered a biomarker associated with the HOXD8 gene that showed high sensitivity and specificity in detecting BTC in tissue and bile samples.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma

Liangqing Dong et al.

Summary: This study performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA) and revealed important features of iCCA pathogenesis. It identified subgroup-specific biomarkers and provided valuable insights into molecular pathogenesis and therapeutic opportunities in iCCA.

CANCER CELL (2022)

Add to Collection

Article Gastroenterology & Hepatology

Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis

Benjamin Goeppert et al.

Summary: A detailed understanding of molecular alterations in different forms of cholangiocarcinogenesis is crucial for early diagnosis and better treatment options for cholangiocarcinoma (CCA). Analyses revealed that invasive CCA arising from IPNB/ITPN had better prognosis, with distinct genetic and epigenetic differences between IPNB and ITPN, representing unique intermediate forms of intrahepatic and extrahepatic cholangiocarcinogenesis.

GUT (2022)

Add to Collection

Article Biochemistry & Molecular Biology

METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m6A-YTHDF2-dependent manner

Qiong-Cong Xu et al.

Summary: This study reveals that METTL3 is upregulated in intrahepatic cholangiocarcinoma (ICC) and predicts poor prognosis. METTL3 expression is an independent predictor of overall survival in ICC patients. METTL3 can be transcriptionally activated by H3K4me3 and mediate m(6)A modification of IFIT2 mRNA, promoting ICC progression.

ONCOGENE (2022)

Add to Collection

Article Medicine, Research & Experimental

Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities

Xiang-Yu Wang et al.

Summary: By analyzing genomic data, we established a clinically applicable genomic clustering system for intrahepatic cholangiocarcinoma (ICC), which can be used for prognostic prediction, molecular classification, and therapeutic optimization.

THERANOSTICS (2022)

Add to Collection

Article Oncology

Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

Funda Meric-Bernstam et al.

Summary: Futibatinib, a selective FGFR1-4 inhibitor, showed clinical activity in various solid tumors, particularly in FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma. It also demonstrated efficacy in patients who developed resistance to prior FGFR inhibitors. These findings provide a basis for further clinical trials and highlight the importance of genomic profiling in identifying patients who may benefit from targeted therapy.

CANCER DISCOVERY (2022)

Add to Collection

Article Cell Biology

Suppression of histone deacetylase 1 by JSL-1 attenuates the progression and metastasis of cholangiocarcinoma via the TPX2/Snail axis

Lu Xu et al.

Summary: In this study, the potential role of HDAC1 inhibitor (JSL-1) in the tumorigenesis and metastasis of cholangiocarcinoma (CC) was explored. The findings showed that high expression of HDAC1 was associated with CC. The inhibition of HDAC1 and downregulation of TPX2 exhibited anti-proliferative, anti-migration, and anti-invasion effects on CC cells, providing potential therapeutic targets for CC.

CELL DEATH & DISEASE (2022)

Add to Collection

Article Multidisciplinary Sciences

Single-cell transcriptomic analysis suggests two molecularly subtypes of intrahepatic cholangiocarcinoma

Guohe Song et al.

Summary: This study characterizes the molecular classification and tumor microenvironment of intrahepatic cholangiocarcinoma (iCCA) using single cell RNA-sequencing. The authors identify S100P and SPP1 as markers for patient classification and demonstrate that different subtypes of iCCA have distinct immune cell infiltration and survival rates.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Multidisciplinary Sciences

The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers

Yaodong Zhang et al.

Summary: This study analyzed exome-sequencing data of perihilar cholangiocarcinoma (pCCA) and intrahepatic cholangiocarcinoma (iCCA) cases from Asian centers and found that iCCA tumors have a higher tumor mutation burden and copy number alteration burden compared to pCCA tumors. The study also identified common mutations in post-transcriptional modification-related potential driver genes METTL14 and RBM10 in pCCA tumors. Furthermore, the study demonstrated the tumor-suppressive role of METTL14.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Genetics & Heredity

TP53/KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma

Chunguang Guo et al.

Summary: This study comprehensively analyzed the clinical and somatic mutation data of ICC patients from large-scale cohorts, and identified TP53 and KRAS as the common high-frequency mutation genes associated with poor prognosis. The study also classified patients into different mutation phenotypes and found that Double-Hit patients had a dismal prognosis and high TMB. Through chemotherapy sensitivity analysis, the study identified several drugs sensitive to ICC patients.

FRONTIERS IN GENETICS (2022)

Add to Collection

Article Oncology

Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1-Mediated Gemcitabine Chemoresistance

Zhiqing Bai et al.

Summary: Recent research has shown that lapatinib can inhibit the growth of CCA cells overexpressing HER2 and overcome ABCB1-mediated chemoresistance following gemcitabine treatment, supporting the potential effectiveness of a combination treatment of lapatinib with gemcitabine in HER2-overexpressed CCA.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study

Do-Youn Oh et al.

Summary: In patients with advanced biliary tract cancer, gemcitabine and cisplatin plus immunotherapy showed promising efficacy and acceptable safety, with an objective response rate of 66%. The most common adverse events were hematological, with no unexpected safety events observed.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Review Medicine, General & Internal

Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma

Taek Chung et al.

Summary: Intrahepatic cholangiocarcinoma (iCCA) is an aggressive primary liver malignancy with distinct histopathologic features and molecular profiles. The classification of small duct type and large duct type iCCA provides important insights into the tumor behavior and prognosis. Understanding the tumor microenvironment and genomic characteristics can help develop precision therapeutics for patients with iCCA.

FRONTIERS IN MEDICINE (2022)

Add to Collection

Article Oncology

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures

Kabir Mody et al.

Summary: The immune landscape of different subtypes of biliary tract cancers (BTCs) can help improve patient selection for immunotherapy and guide treatment strategies. The study revealed diverse genetic alterations and immune biomarkers in BTC subtypes, with gallbladder cancer and specific genetic mutations associated with the immune microenvironment.

JCO PRECISION ONCOLOGY (2022)

Add to Collection

Article Oncology

Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response

Kristen Bibeau et al.

Summary: This study investigated the progression-free survival (PFS) in patients with advanced/metastatic cholangiocarcinoma who received first- or second-line systemic therapy. The results showed that, among patients with FGFR2 fusions/rearrangements, treatment with pemigatinib as second-line therapy may be associated with longer PFS compared to previous systemic therapy.

JCO PRECISION ONCOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumors display divergent genomic and transcriptomic profiles

Michele Simbolo et al.

Summary: PHCC demonstrated more frequent KRAS mutations, while TP53 mutations were more common in DECC. Potentially actionable alterations included high tumor mutational burden and/or microsatellite instability (7.1%), PI3KCA mutations (8.1%), and MYC (10.1%) and ERBB2 amplification (5.1%). Transcriptomic profiles revealed three distinct clusters, corresponding to anatomical origin and differing in immune microenvironment. DECC appeared to consist of two distinct tumor subgroups, one enriched for druggable alterations and one lacking actionable opportunities.

EXPERT OPINION ON THERAPEUTIC TARGETS (2021)

Add to Collection

Article Oncology

Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

Ian M. Silverman et al.

Summary: The study utilized genomic profiling data to explore the genomic landscape and molecular diversity of patients with cholangiocarcinoma, as well as analyze the clinicogenomics of patients treated with pemigatinib, highlighting the utility of genomic profiling in clinical trials.

CANCER DISCOVERY (2021)

Add to Collection

Article Oncology

ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway

Oded Jacobi et al.

Summary: The study described the genomic landscape of CCA patients using NGS, identifying potential targetable alterations in the ERBB/EGFR pathway and suggesting efficacy of anti-HER2 agents in certain patients. Further investigations are warranted to explore the clinical significance of these findings.

ONCOLOGY RESEARCH AND TREATMENT (2021)

Add to Collection

Article Gastroenterology & Hepatology

Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses

Jihoon G. Yoon et al.

Summary: This study identified predictive molecular features of chemotherapy and immunotherapy responses in advanced BTCs using clinical sequencing platforms. The results offer an intuitive framework to guide treatment based on the tumors' molecular features.

HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma

Thomas Boerner et al.

Summary: Genetic alterations in iCCA, including TP53, KRAS, and CDKN2A mutations, are associated with poorer prognosis, especially in advanced disease, independent of clinical and pathological variables. Combining targeted tumor sequencing with clinical variables may help identify patient subgroups with poor outcomes, regardless of treatment strategy.

HEPATOLOGY (2021)

Add to Collection

Article Pathology

Reappraisal of pathological features of intraductal papillary neoplasm of bile duct with respect to the type 1 and 2 subclassifications

Yasuni Nakanuma et al.

Summary: Intraductal papillary neoplasm of bile duct (IPNB) can be classified into type 1 (low-grade dysplasia and 'high-grade dysplasia with regular structures') and type 2 ('high-grade dysplasia with irregular structures and complicated lesions'), with different distribution and mucin hypersecretion patterns. The four subtypes exhibit varied characteristics in type 1 and 2, and stromal invasion is significantly correlated with postoperative outcomes.

HUMAN PATHOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

Milind Javle et al.

Lancet Gastroenterology & Hepatology (2021)

Add to Collection

Article Oncology

Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma

Yuanwen Zheng et al.

Summary: The study identified significant mutational differences between perihilar CCA (pCCA) and distal CCA (dCCA) within extrahepatic CCA (exCCA), leading to different prognoses. Additionally, certain gene mutations were found to be associated with tumor mutational burden (TMB), potentially serving as biomarkers for treatment prediction.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

Milind Javle et al.

Summary: The study evaluated the activity of pertuzumab plus trastuzumab in patients with HER2-positive metastatic biliary tract cancer. The results showed a promising response rate and good tolerability, suggesting the need for further randomized, controlled trials in this patient population.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Genetic Screens Identify a Context-Specific PI3K/p27Kip1 Node Driving Extrahepatic Biliary Cancer

Chiara Falcomata et al.

Summary: This study utilized a genetically engineered mouse model to identify cancer genes for extrahepatic bile duct carcinoma through genome-wide transposon-based mutagenesis screening. The findings demonstrate that PI3K signaling output strength and p27(Kip1) function are critical determinants for context-specific ECC formation.

CANCER DISCOVERY (2021)

Add to Collection

Article Multidisciplinary Sciences

Transformation of SOX9+ cells by Pten deletion synergizes with steatotic liver injury to drive development of hepatocellular and cholangiocarcinoma

Jingyu Chen et al.

Summary: The research indicates that SOX9(+) cells play a crucial role in liver carcinogenesis, and the loss of gene PTEN induces the transformation of these cells. Liver injury is crucial for promoting the activation and proliferation of transformed SOX9(+) cells.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Multidisciplinary Sciences

Primary sclerosing cholangitis and the risk of cancer, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of cohort studies

Dagfinn Aune et al.

Summary: A diagnosis of primary sclerosing cholangitis is strongly associated with an increased risk of hepatobiliary cancers, colorectal cancer, and all-cause mortality, but not with cardiovascular disease.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Medicine, General & Internal

Cholangiocarcinoma

Paul J. Brindley et al.

Summary: Cholangiocarcinoma is a highly lethal adenocarcinoma of the hepatobiliary system that can be associated with liver fluke infection but often has no identifiable cause. This Primer reviews the epidemiology, pathophysiological mechanisms, diagnosis and management of cholangiocarcinoma, and highlights the patient experience and future directions.

NATURE REVIEWS DISEASE PRIMERS (2021)

Add to Collection

Article Oncology

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation The Phase 3 Randomized Clinical ClarIDHy Trial

Andrew X. Zhu et al.

Summary: The study found that ivosidenib was well tolerated and led to a favorable overall survival benefit compared to placebo, despite a high crossover rate.

JAMA ONCOLOGY (2021)

Add to Collection

Article Oncology

Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma

Karthikeyan Murugesan et al.

Summary: The study analyzed the genomic profiles of combined hepatocellular cholangiocarcinoma (cHCC-CCA) to establish a machine learning model for classifying cHCC-CCA as CCA-like or HCC-like. This research demonstrates the potential of using machine learning models in clinical practice to classify cHCC-CCA.

JCO PRECISION ONCOLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis

Oliver Clements et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Clinicopathological characteristics of intrahepatic cholangiocarcinoma according to gross morphologic type: cholangiolocellular differentiation traits and inflammation-and proliferation-phenotypes

Taek Chung et al.

HPB (2020)

Add to Collection

Article Gastroenterology & Hepatology

Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities

Benjamin Goeppert et al.

HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma

Sylvie Job et al.

HEPATOLOGY (2020)

Add to Collection

Article Oncology

Intraductal papillary neoplasms of the bile duct consist of two distinct types specifically associated with clinicopathological features and molecular phenotypes

Yasutaka Aoki et al.

JOURNAL OF PATHOLOGY (2020)

Add to Collection

Article Oncology

FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.

Lipika Goyal et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma

Robert Montal et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Article Oncology

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou-Alfa et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer

Richard D. Kim et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements

Tanios S. Bekaii-Saab et al.

FUTURE ONCOLOGY (2020)

Add to Collection

Article Oncology

Molecular profile of BRCA-mutated biliary tract cancers

Gilbert Spizzo et al.

ESMO OPEN (2020)

Add to Collection

Article Gastroenterology & Hepatology

Cholangiocarcinoma 2020: the next horizon in mechanisms and management

Jesus M. Banales et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)

Add to Collection

Article Oncology

Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

Vivek Subbiah et al.

LANCET ONCOLOGY (2020)

Add to Collection

Review Oncology

Evolution of the Experimental Models of Cholangiocarcinoma

Annamaria Massa et al.

CANCERS (2020)

Add to Collection

Review Medicine, General & Internal

Intraductal Papillary Neoplasm of Bile Duct: Updated Clinicopathological Characteristics and Molecular and Genetic Alterations

Yasuni Nakanuma et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Article Oncology

Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients

Jingyu Cao et al.

JCO PRECISION ONCOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Neoplastic Transformation of the Peribiliary Stem Cell Niche in Cholangiocarcinoma Arisen in Primary Sclerosing Cholangitis

Guido Carpino et al.

HEPATOLOGY (2019)

Add to Collection

Article Oncology

Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma

Nancy M. Joseph et al.

JOURNAL OF PATHOLOGY (2019)

Add to Collection

Review Gastroenterology & Hepatology

Cholangiocarcinoma: Epidemiology and risk factors

Shahid A. Khan et al.

LIVER INTERNATIONAL (2019)

Add to Collection

Review Gastroenterology & Hepatology

Cholangiocyte pathobiology

Jesus M. Banales et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)

Add to Collection

Article Oncology

Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes

Ruidong Xue et al.

CANCER CELL (2019)

Add to Collection

Meeting Abstract Oncology

Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.

Yung-Jue Bang et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Pathology

Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct

Ching-Yao Yang et al.

MODERN PATHOLOGY (2019)

Add to Collection

Article Oncology

831TiPA phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1

D-Y Oh et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma

Benjamin Goeppert et al.

HEPATOLOGY (2019)

Add to Collection

Review Oncology

Epigenome Remodeling in Cholangiocarcinoma

Colm J. O'Rourke et al.

TRENDS IN CANCER (2019)

Add to Collection

Article Oncology

Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma

Margaret A. Hill et al.

CANCER RESEARCH (2018)

Add to Collection

Article Gastroenterology & Hepatology

Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma

Chirag Nepal et al.

HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations

Christopher P. Wardell et al.

JOURNAL OF HEPATOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma

Anqiang Wang et al.

NATURE COMMUNICATIONS (2018)

Add to Collection

Article Gastroenterology & Hepatology

Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity

Agrin Moeini et al.

JOURNAL OF HEPATOLOGY (2017)

Add to Collection

Article Pathology

Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas

Masayuki Akita et al.

MODERN PATHOLOGY (2017)

Add to Collection

Article Oncology

Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma

Apinya Jusakul et al.

CANCER DISCOVERY (2017)

Add to Collection

Article Pathology

Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma

Akimasa Hayashi et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)

Add to Collection

Article Multidisciplinary Sciences

Notch3 drives development and progression of cholangiocarcinoma

Rachel V. Guest et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)

Add to Collection

Article Oncology

Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans

L. Che et al.

ONCOGENESIS (2016)

Add to Collection

Article Gastroenterology & Hepatology

Activation of biliary tree stem cells within peribiliary glands in primary sclerosing cholangitis

Guido Carpino et al.

JOURNAL OF HEPATOLOGY (2015)

Add to Collection

Article Pathology

Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases

Anna Melissa Schlitter et al.

MODERN PATHOLOGY (2015)

Add to Collection

Article Multidisciplinary Sciences

Cell-of-origin chromatin organization shapes the mutational landscape of cancer

Paz Polak et al.

NATURE (2015)

Add to Collection

Article Genetics & Heredity

Genomic spectra of biliary tract cancer

Hiromi Nakamura et al.

NATURE GENETICS (2015)

Add to Collection

Article Gastroenterology & Hepatology

Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type

Shinichi Aishima et al.

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2015)

Add to Collection

Article Gastroenterology & Hepatology

Global Alterations of DNA Methylation in Cholangiocarcinoma Target the Wnt Signaling Pathway

Benjamin Goeppert et al.

HEPATOLOGY (2014)

Add to Collection

Article Pathology

Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features

Jau-Yu Liau et al.

MODERN PATHOLOGY (2014)

Add to Collection

Article Pathology

Cystic and micropapillary epithelial changes of peribiliary glands might represent a precursor lesion of biliary epithelial neoplasms

Yasunori Sato et al.

VIRCHOWS ARCHIV (2014)

Add to Collection

Article Oncology

A Critical Role for Notch Signaling in the Formation of Cholangiocellular Carcinomas

Steffen Zender et al.

CANCER CELL (2013)

Add to Collection

Article Gastroenterology & Hepatology

Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes

Daniela Sia et al.

GASTROENTEROLOGY (2013)

Add to Collection

Article Oncology

PTEN loss and KRAS activation cooperate in murine biliary tract malignancies

Victoria Marsh et al.

JOURNAL OF PATHOLOGY (2013)

Add to Collection

Article Multidisciplinary Sciences

Activation of Notch Signaling Is Required for Cholangiocarcinoma Progression and Is Enhanced by Inactivation of p53 In Vivo (Publication with Expression of Concern. See vol. 14, 2019)

Mona El Khatib et al.

PLOS ONE (2013)

Add to Collection

Article Oncology

KrasG12D and p53 Mutation Cause Primary intrahepatic Cholangiocarcinoma

Michael R. O'Dell et al.

CANCER RESEARCH (2012)

Add to Collection

Letter Gastroenterology & Hepatology

Cystic and papillary neoplasm involving peribiliary glands: A biliary counterpart of branch-type intraductal papillary mucinous cystic neoplasm?

Yasuni Nakanuma et al.

HEPATOLOGY (2012)

Add to Collection

Article Gastroenterology & Hepatology

Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes

Mina Komuta et al.

HEPATOLOGY (2012)

Add to Collection

Article Medicine, Research & Experimental

Cholangiocarcinomas can originate from hepatocytes in mice

Biao Fan et al.

JOURNAL OF CLINICAL INVESTIGATION (2012)

Add to Collection

Article Medicine, Research & Experimental

Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes

Sayaka Sekiya et al.

JOURNAL OF CLINICAL INVESTIGATION (2012)

Add to Collection

Review Biochemistry & Molecular Biology

Molecular mechanisms of bile duct development

Yiwei Zong et al.

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2011)

Add to Collection

Article Gastroenterology & Hepatology

Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin

Mina Komuta et al.

HEPATOLOGY (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.